Viking Therapeutics – Patient Worthy

source: pixabay.com

VK2809 for NASH Significantly Reduces LDL Cholesterol, Liver Fat

Post author:Jessica Lynn
Post published:November 30, 2020
Post category:Adrenoleukodystrophy Nonalcoholic steatohepatitis

In November 2020, Viking Therapeutics ("Viking") shared insight into their metabolic disease program. According to Greg Zante, the Senior VP (SVP) of Finance for Viking, the company's treatment VK2809, licensed…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More